You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 5,736,137

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,736,137

Title:	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Abstract:	Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Inventor(s):	Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Olivenhain, CA), Leonard; John E. (Encinitas, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Sante Fe, CA)
Assignee:	Idec Pharmaceuticals Corporation (San Diego, CA)
Application Number:	08/149,099
Patent Claims:	1. Immunologically active, chimeric anti-CD20 antibody produced from a transfectoma comprising anti-CD20 in TCAE 8, ATCC deposit number 69119. 2. A pharmaceutical composition comprising the anti-CD20 antibody of claim 1 in a pharmaceutically acceptable carrier. 3. The composition of claim 2, which contains a pharmaceutically acceptable carrier or excipient selected from the group consisting of sterile saline, sterile buffered water, propylene glycol and mixtures thereof. 4. The composition of claim 2, which contains a pharmaceutically acceptable dosage of the antibody which ranges from about 0.001 to about 30 mg/kg of human body weight. 5. The composition of claim 4, which contains a pharmaceutically acceptable dosage of the antibody which ranges from about 0.01 to about 25 mg/kg human body weight. 6. The composition of claim 5, which contains a pharmaceutically acceptable dosage of the antibody which ranges from about 0.4 to about 20.0 mg/kg human body weight.

Details for Patent 5,736,137

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Acrotech Biopharma Llc	ZEVALIN	ibritumomab tiuxetan	Injection	125019	02/19/2002	⤷ Try a Trial	2015-04-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,736,137

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Austria	139900	⤷ Try a Trial
Austria	196606	⤷ Try a Trial
Austria	421335	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.